Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
208.75
-4.53 (-2.12%)
At close: Jan 8, 2026, 4:00 PM EST
212.88
+4.13 (1.98%)
After-hours: Jan 8, 2026, 4:56 PM EST
Ascendis Pharma Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
$745,912
Profits / Employee
-$268,740
Market Cap
12.81B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ASND News
- 3 hours ago - Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - GlobeNewsWire
- 3 days ago - Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 24 days ago - Here's My Prediction For Who Could Acquire Ascendis Pharma - Seeking Alpha
- 4 weeks ago - Eight stock picks to play one of the healthiest corners of the market - Market Watch
- 4 weeks ago - High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth - Seeking Alpha
- 4 weeks ago - Ascendis: Q3 Results Validate The TransCon Platform - Seeking Alpha
- 5 weeks ago - Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Benzinga
- 6 weeks ago - US FDA extends review of Ascendis Pharma's therapy for children with dwarfism - Reuters